Shots:

• Eli Lilly and Dicerna have reported the US FDA’s IND acceptance of LY3819469 to treat cardiometabolic diseases. The IND acceptance triggers $10M as a milestone to Dicerna under the companies’ 2018 research collaboration and licensing agreement
• LY3819469 is an investigational GalXC RNAi candidate targeting the LPA gene and is the second clinical-stage candidate to emerge from Dicerna’s collaboration with Lilly
• As per the agreement- Dicerna is eligible to receive ~$350M in development & commercialization milestones for each GalXC hepatocyte target and $355M for each non-hepatocyte target along with royalties on product sales

  Ref: Businesswire | Image: Eli Lilly